Related Experiment Video

Updated: May 29, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Advances in the management of pediatric pulmonary hypertension

Peter Oishi1, Sanjeev A Datar, Jeffrey R Fineman

  • 1Division of Pediatric Critical Care Medicine, University of California, San Francisco, California 94143-1346, USA.

Respiratory Care
|September 28, 2011
PubMed

Insights

Pediatric pulmonary hypertension is a rare, serious condition with limited understanding and treatments. Research is advancing, focusing on endothelial pathways to improve outcomes for children with this disease.

Area of Science:

  • Pediatric Cardiology
  • Neonatal Medicine
  • Pulmonary Vascular Disease

Background:

  • Pulmonary hypertension (PH) in neonates, infants, and children is a rare condition with high morbidity and mortality.
  • Understanding of its pathophysiology is limited, with a specific lack of research in pediatric populations.
  • Current therapeutic options for pediatric PH are restricted.

Purpose of the Study:

  • To review the epidemiology, pathophysiology, current treatments, and emerging therapies for neonatal and pediatric pulmonary hypertension.
  • To highlight the knowledge gaps in understanding the mechanisms controlling pediatric PH.
  • To discuss the limitations of current therapeutic strategies.

Main Methods:

  • Review of existing literature on pediatric pulmonary hypertension.
  • Analysis of pathophysiologic mechanisms, including endothelial-derived factors.
  • Examination of current and novel therapeutic approaches.

Main Results:

  • Advanced PH involves progressive pulmonary vascular changes leading to right-ventricular failure and death.
  • Management strategies focus on vasoconstriction, right-ventricular support, and underlying disease treatment.
  • Current therapies target nitric oxide/cGMP, prostacyclin, and endothelin-1 pathways.

Conclusions:

  • Reversing advanced structural changes in pediatric PH remains a significant challenge.
  • Further research is crucial to elucidate pathophysiologic mechanisms and develop effective treatments for pediatric PH.
  • Emerging therapies offer potential for improved management of this rare disease.

More Related Videos

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...